Gregory A Abel

List of Publications by Year
in descending order

112 papers	2,953 citations	168829 31 h-index	214428 50 g-index
113 all docs	113 docs citations	113 times ranked	3669 citing authors

#	Article	IF	Citations
1	Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica, 2022, 107, 1172-1180.	1.7	21
2	Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 2022, 139, 1246-1250.	0.6	15
3	Virtual frailty assessment for older adults with hematologic malignancies. Blood Advances, 2022, 6, 5360-5363.	2.5	5
4	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. Journal of Clinical Oncology, 2022, 40, 3709-3718.	0.8	9
5	A Process Framework for Ethically Deploying Artificial Intelligence in Oncology. Journal of Clinical Oncology, 2022, 40, 3907-3911.	0.8	6
6	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. Leukemia, 2021, 35, 1166-1175.	3.3	5
7	Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer, 2021, 127, 875-883.	2.0	16
8	Defining Multimorbidity and Its Impact in Older United States Veterans Newly Treated for Multiple Myeloma. Journal of the National Cancer Institute, 2021, 113, 1084-1093.	3.0	10
9	Objective performance tests of cognition and physical function as part of a virtual geriatric assessment. Journal of Geriatric Oncology, 2021, 12, 1256-1258.	0.5	2
10	Prevalence and Tolerance of Prognostic Uncertainty Among Thoracic Oncologists. Oncologist, 2021, 26, e1480-e1482.	1.9	10
11	Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematology,the, 2021, 8, e246-e248.	2.2	1
12	Advances in Management for Older Adults With Hematologic Malignancies. Journal of Clinical Oncology, 2021, 39, 2102-2114.	0.8	24
13	Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	0
14	Periâ€transfusion qualityâ€ofâ€life assessment for patients with myelodysplastic syndromes. Transfusion, 2021, 61, 2830-2836.	0.8	10
15	Impact of Polypharmacy and Potentially Inappropriate Medications Among Older Adults with Blood Cancers. Blood, 2021, 138, 4089-4089.	0.6	0
16	Stakeholder Perceptions of Barriers to Diverse Acute Myeloid Leukemia Clinical Trial Enrollment at Comprehensive Cancer Centers. Blood, 2021, 138, 3014-3014.	0.6	0
17	Virtual Versus in-Person Frailty Assessments in Older Adults with Hematologic Malignancies. Blood, 2021, 138, 2997-2997.	0.6	0
18	Validation of the Qualms Questionnaire to Assess Health-Related Quality of Life in European and Israeli Patients with Myelodysplastic Syndromes: Results from the MDS-Right Project. Blood, 2021, 138, 1982-1982.	0.6	1

#	Article	IF	Citations
19	Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation. Bone Marrow Transplantation, 2020, 55, 242-244.	1.3	3
20	Goals of care discussions for patients with blood cancers: Association of person, place, and time with endâ€ofâ€life care utilization. Cancer, 2020, 126, 515-522.	2.0	37
21	Patientâ€hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study. Cancer, 2020, 126, 1306-1314.	2.0	24
22	Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions. Leukemia and Lymphoma, 2020, 61, 2900-2904.	0.6	10
23	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Advances, 2020, 4, 3528-3549.	2.5	113
24	Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. Journal of Pain and Symptom Management, 2020, 59, 1195-1203.e4.	0.6	18
25	An Action Plan for Environmentally Sustainable Cancer Care. JAMA Oncology, 2020, 6, 469.	3.4	5
26	Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review. Journal of Clinical Oncology, 2020, 38, 2558-2569.	0.8	110
27	The Impact of Different Ethical Allocation Strategies on Survival during Vincristine Shortages. Blood, 2020, 136, 59-60.	0.6	1
28	Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study. Blood, 2020, 136, 15-16.	0.6	2
29	Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist, 2019, 24, 247-254.	1.9	55
30	Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer, 2019, 125, 3845-3852.	2.0	10
31	Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood, 2019, 134, 374-382.	0.6	131
32	The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leukemia and Lymphoma, 2019, 60, 3161-3171.	0.6	12
33	Relationship between paid leave, financial burden, and patient-reported outcomes among employed patients who have undergone bone marrow transplantation. Quality of Life Research, 2019, 28, 1835-1847.	1.5	15
34	Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia, 2019, 33, 2393-2402.	3.3	44
35	How Do Blood Cancer Doctors Discuss Prognosis? Findings from a National Survey of Hematologic Oncologists. Journal of Palliative Medicine, 2019, 22, 677-684.	0.6	20
36	Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. Journal of the American Geriatrics Society, 2019, 67, 889-897.	1.3	28

#	Article	IF	Citations
37	Perceptions of Oncologists About Sharing Clinic Notes with Patients. Oncologist, 2019, 24, e46-e48.	1.9	2
38	Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older. Journal of Geriatric Oncology, 2019, 10, 486-489.	0.5	24
39	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. Biology of Blood and Marrow Transplantation, 2019, 25, 599-605.	2.0	20
40	Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncology, 2018, 4, 686.	3.4	83
41	Cancer drug shortages: Awareness and perspectives from a representative sample of the US population. Cancer, 2018, 124, 2205-2211.	2.0	6
42	Management of older adults with myelodysplastic syndromes (MDS). Journal of Geriatric Oncology, 2018, 9, 302-307.	0.5	12
43	Patientâ€reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. Cancer, 2018, 124, 1251-1259.	2.0	31
44	Frailty and the management of hematologic malignancies. Blood, 2018, 131, 515-524.	0.6	146
45	What Does a Cancer Diagnosis Mean? Public Expectations in a Shifting Therapeutic Environment. Journal of Oncology Practice, 2018, 14, 139-140.	2.5	1
46	Cognitive Impairment Among Older Patients With Hematologic Cancersâ€”Reply. JAMA Oncology, 2018, 4, 1784.	3.4	1
47	What is the Role of the Arts in Medical Education and Patient Care? A Survey-based Qualitative Study. Journal of Medical Humanities, 2018, 39, 431-445.	0.3	6
48	Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 345-347.	1.1	6
49	Impact of lenalidomide use among nonâ€transfusion dependent patients with myelodysplastic syndromes. American Journal of Hematology, 2018, 93, 1119-1126.	2.0	8
50	Meaningful changes in end-of-life care among patients with myeloma. Haematologica, 2018, 103, 1380-1389.	1.7	24
51	Selfâ€reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology, 2017, 177, 562-566.	1.2	16
52	Why are patients with blood cancers more likely to die without hospice?. Cancer, 2017, 123, 3377-3384.	2.0	61
53	Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis Research, 2017, 150, 53-58.	0.8	9
54	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia and Lymphoma, 2017, 58, 982-985.	0.6	16

#	Article	IF	Citations
55	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Advances, 2017, 1, 2032-2040.	2.5	53
56	Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS ONE, 2017, 12, e0184747.	1.1	9
57	Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. British Journal of Haematology, 2016, 173, 713-721.	1.2	7
58	High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1274-1281.	2.3	7
59	Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematology,the, 2016, 3, e276-e283.	2.2	19
60	Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies. British Journal of Cancer, 2016, 115, 858-861.	2.9	20
61	Assessing Quality of Care for the Myelodysplastic Syndromes. Current Hematologic Malignancy Reports, 2016, 11, 402-407.	1.2	5
62	Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health. JAMA Oncology, 2016, 2, 1397.	3.4	9
63	Barriers to Quality End-of-Life Care for Patients With Blood Cancers. Journal of Clinical Oncology, 2016, 34, 3126-3132.	0.8	108
64	Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal of Haematology, 2016, 175, 829-840.	1.2	59
65	Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica, 2016, 101, 781-788.	1.7	50
66	Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1504-1510.	2.0	63
67	Novel Data Sharing Between a Comprehensive Cancer Center and a Private Payer to Better Understand Care at the End of Life. Journal of Pain and Symptom Management, 2016, 52, 161-169.	0.6	8
68	Intensity of endâ€ofâ€life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer, 2016, 122, 1209-1215.	2.0	44
69	Hospice Use Among Patients With Lymphoma: Impact of Disease Aggressiveness and Curability. Journal of the National Cancer Institute, 2016, 108, djv280.	3.0	47
70	Timeliness of End-of-Life Discussions for Blood Cancers. JAMA Internal Medicine, 2016, 176, 263.	2.6	45
71	Patient-Reported Outcomes Associated with Different Treatments for Myelodysplastic Syndromes. Blood, 2016, 128, 3602-3602.	0.6	1
72	Measurement and Prevalence of Cognitive Impairment in Older Patients with Hematologic Malignancies. Blood, 2016, 128, 689-689.	0.6	1

#	Article	IF	Citations
73	Integrating Frailty, Comorbidity, and Quality of Life in the Management of Myelodysplastic Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e337-e344.	1.8	8
74	Accessibility and Quality of Online Cancer-Related Clinical Trial Information for NaÃ¯ve Searchers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1629-1631.	1.1	15
75	Health care utilization and endâ€ofâ€life care for older patients with acute myeloid leukemia. Cancer, 2015, 121, 2840-2848.	2.0	113
76	Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. Journal of Geriatric Oncology, 2015, 6, 288-298.	0.5	29
77	Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leukemia and Lymphoma, 2015, 56, 716-724.	0.6	37
78	Prevalence and Impact of Financial Hardship among New England Pediatric Stem Cell Transplantation Families. Biology of Blood and Marrow Transplantation, 2015, 21, 312-318.	2.0	52
79	Does Surveillance Imaging After Treatment for Diffuse Large B-Cell Lymphoma Really Work?. Journal of Clinical Oncology, 2015, 33, 1427-1429.	0.8	5
80	Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study. Blood, 2015, 126, 3306-3306.	0.6	2
81	Cost-Effectiveness Analysis of Warfarin Versus Low-Molecular Weight Heparin for the Treatment of Malignancy-Associated Venous Thromboembolism. Blood, 2015, 126, 746-746.	0.6	9
82	Public Advertising by Cancer Centers: Are More Data Needed?. Annals of Internal Medicine, 2014, 160, 870.	2.0	2
83	Reply to quality control of bone marrow aspirates: Additional steps toward a safer and more efficient procedure. Cancer, 2014, 120, 1442-1442.	2.0	0
84	Derivation and validation of the SEER-Medicare myelodysplastic syndromes risk score (SMMRS). Leukemia Research, 2014, 38, 1420-1424.	0.4	9
85	End-of-Life Care for Blood Cancers: A Series of Focus Groups With Hematologic Oncologists. Journal of Oncology Practice, 2014, 10, e396-e403.	2.5	142
86	Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood, 2014, 123, 451-452.	0.6	27
87	Improving the quality of bone marrow assessment. Cancer, 2013, 119, 3472-3478.	2.0	17
88	Impact of oncologyâ€related directâ€toâ€consumer advertising. Cancer, 2013, 119, 1065-1072.	2.0	14
89	A novel community-based delivery model to combat cancer disparities. Healthcare, 2013, 1, 123-129.	0.6	2
90	Optimal positioning of hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. Current Opinion in Hematology, 2013, 20, 150-156.	1.2	13

#	Article	IF	Citations
91	Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States. Journal of Clinical Oncology, 2013, 31, 1984-1989.	0.8	86
92	Update on Direct-to-Consumer Marketing in Oncology. Journal of Oncology Practice, 2012, 8, 124-127.	2.5	13
93	High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leukemia and Lymphoma, 2012, 53, 1113-1116.	0.6	38
94	Referrals for suspected hematologic malignancy: A survey of primary care physicians. American Journal of Hematology, 2012, 87, 634-636.	2.0	15
95	Lack of benefit of central nervous system prophylaxis for diffuse large Bâ€cell lymphoma in the rituximab era. Cancer, 2012, 118, 2944-2951.	2.0	78
96	Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nursesâ€™ Health Study. Cancer Causes and Control, 2011, 22, 1731-1741.	0.8	39
97	Timeliness and quality of diagnostic care for medicare recipients with chronic lymphocytic leukemia. Cancer, 2011, 117, 1470-1477.	2.0	25
98	Outcomes for lymphoid malignancies in the Nurses' Health Study (NHS) as compared to the Surveillance, Epidemiology and End Results (SEER) Program. Hematological Oncology, 2010, 28, 133-136.	0.8	5
99	Classification of the myelodysplastic syndrome in a national registry of recently diagnosed patients. Leukemia Research, 2010, 34, 939-941.	0.4	5
100	Cancer-Related Direct-to-Consumer Advertising: Awareness, Perceptions, and Reported Impact Among Patients Undergoing Active Cancer Treatment. Journal of Clinical Oncology, 2009, 27, 4182-4187.	0.8	41
101	Diagnostic delay and complications for older adults with multiple myeloma. Leukemia and Lymphoma, 2009, 50, 392-400.	0.6	59
102	R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project.. Blood, 2009, 114, 403-403.	0.6	8
103	Diagnostic Delays and Survival for Medicare Patients with Chronic Myeloid Leukemia in the Pre-Imatinib Era.. Blood, 2009, 114, 1369-1369.	0.6	0
104	Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database.. Blood, 2009, 114, 1387-1387.	0.6	15
105	Chemotherapy as language: Sound symbolism in cancer medication names. Social Science and Medicine, 2008, 66, 1863-1869.	1.8	52
106	Delays in referral and diagnosis for chronic hematologic malignancies: A literature review. Leukemia and Lymphoma, 2008, 49, 1352-1359.	0.6	22
107	Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network. Journal of Clinical Oncology, 2008, 26, 5107-5112.	0.8	75
108	Direct-to-Consumer Advertising in Oncology: A Content Analysis of Print Media. Journal of Clinical Oncology, 2007, 25, 1267-1271.	0.8	23

#	Article	IF	Citations
109	Predictors of Diagnosis Delay and Complications for Newly-Diagnosed Myeloma Patients.. Blood, 2007, 110, 368-368.	0.6	2
110	JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. Blood, 2007, 110, 1634-1634.	0.6	0
111	Effects of Biochemically Confirmed Smoking Cessation on White Blood Cell Count. Mayo Clinic Proceedings, 2005, 80, 1022-1028.	1.4	54
112	Peripheral blood <scp>CD3</scp> ⁺ Tâ€cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. British Journal of Haematology, 0, , .	1.2	1